Dr. Reddy’s Laboratories Ltd $RDY Shares Acquired by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG increased its holdings in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 912.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 344,786 shares of the company’s stock after acquiring an additional 310,737 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Dr. Reddy’s Laboratories were worth $4,841,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of RDY. Invesco Ltd. increased its holdings in shares of Dr. Reddy’s Laboratories by 7.6% in the 2nd quarter. Invesco Ltd. now owns 253,342 shares of the company’s stock valued at $3,808,000 after acquiring an additional 17,907 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after acquiring an additional 1,294 shares during the period. First Trust Advisors LP increased its holdings in shares of Dr. Reddy’s Laboratories by 23.3% in the 2nd quarter. First Trust Advisors LP now owns 65,652 shares of the company’s stock valued at $987,000 after acquiring an additional 12,390 shares during the period. Sei Investments Co. increased its holdings in shares of Dr. Reddy’s Laboratories by 37.3% in the 2nd quarter. Sei Investments Co. now owns 124,136 shares of the company’s stock valued at $1,866,000 after acquiring an additional 33,747 shares during the period. Finally, Quantinno Capital Management LP increased its holdings in shares of Dr. Reddy’s Laboratories by 92.6% in the 2nd quarter. Quantinno Capital Management LP now owns 235,044 shares of the company’s stock valued at $3,533,000 after acquiring an additional 112,988 shares during the period. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $13.59 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.38 and a current ratio of 1.88. The stock has a market capitalization of $11.34 billion, a P/E ratio of 17.64, a P/E/G ratio of 19.94 and a beta of 0.35. The company’s fifty day moving average is $13.84 and its two-hundred day moving average is $13.87. Dr. Reddy’s Laboratories Ltd has a 1 year low of $12.77 and a 1 year high of $16.17.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $969.81 million for the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a net margin of 16.41% and a return on equity of 15.89%. On average, sell-side analysts predict that Dr. Reddy’s Laboratories Ltd will post 0.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group cut shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a report on Thursday. Weiss Ratings cut shares of Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, February 13th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.90.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.